Human Genome Sciences elects Melvin D. Booth president and chief operating officer.ROCKVILLE, Md.--(BUSINESS WIRE)--July 17, 1995--Human Genome Sciences Inc. (HGS HGS Human Genome Sciences, Inc. (Rockville, Maryland) HGS Heads Up Guidance System HGS Halifax Grammar School (Halifax, Canada) HGS Hangars HGS Heckmondwike Grammar School (UK) , NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : HGSI HGSI Human Genome Sciences, Inc. (Rockville, MD) ) announced today that Melvin D. Booth was elected president and chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. and a director of the corporation. Booth will report to the chairman of the board and chief executive officer, William A. Haseltine, Ph.D. Booth was most recently the president of Syntex Laboratories Inc. He also served as a vice president of Syntex Corporation and as a member of the Oversight Committee for the Syntex/Procter & Gamble Co. joint venture, which launched Aleve(R)(naproxen sodium naproxen sodium Aflaxen, Aleve, Anaprox, Anaprox DS, Apo-Napro-Na (CA), Apo-Napro-Na DS (CA), Arthroxen (UK), Napratec (UK), Naprelan, Novo-Naprox Sodium (CA), Novo-Naprox Sodium DS (CA), Synflex (CA), Synflex (UK) Pharmacologic class: ) in 1994. "We are delighted that Mel Booth will be joining Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. as president and chief operating officer," said Chairman and Chief Executive Officer William A. Haseltine, Ph.D. "HGS's strategic goals call for maximizing the commercial opportunities of our leading technology in genomic research, through collaborations and co-development with large pharmaceutical companies in the near term and development and marketing of our own products in the longer term. Mr. Booth's strong background and experience in strategic planning, pharmaceutical sales and marketing will help the company achieve its strategic goals." Booth's 20 year tenure with Syntex includes serving as president of Syntex Pharmaceuticals Pacific, president of Syntex Canada, and president of Syntex Dental Products Inc. He has been active in U.S. pharmaceutical industry organizations and is also a past chairman of the Pharmaceutical Manufacturers Association of Canada. Booth recently successfully restructured Syntex's U.S. pharmaceutical business, after earlier directing the rebuilding of its Pacific and Canadian business units. Through innovative strategy and strong implementation, the sales and earnings growth of the Pacific and Canadian business were dramatically improved. Under his leadership, Syntex's Canadian unit achieved five new product marketing approvals from Canada's Health Protection Branch over a three year period. Human Genome Sciences Inc. is a company with the mission to develop products to predict, prevent, detect, treat and cure disease based on its leadership in the discovery and understanding of human and microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. genes. CONTACT: Human Genome Sciences, Rockville William A. Haseltine, Ph.D, 301/309-8504 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion